Searched for
GLAXO PHARMA
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma's...
- GlaxoSmithKline Pharma Q4 Results: Firm posts net loss at Rs 55 croreRevenue from operations rose to Rs 810 crore for the fourth quarter compared to Rs 744 crore in the year-ago period, GlaxoSmithKline Pharma...
- GSK Pharma shares slump over 8% ahead of closure of open offerShares of GlaxoSmithKline Pharmaceuticals slumped over 8 per cent as the open offer made by its UK-based parent to acquire additional stake...
- Underweight on MNC pharma stocks, prefer domestic companies: Pramerica MF"The focus is more on domestic pharma company which have a base in domestic market as well as they have base," Mantri said.
- FIPB clears GlaxoSmithKline's Rs 6,400 cr FDI proposalFIPB today cleared Rs 6,400 crore FDI proposal of GlaxoSmithKline to acquire additional 24.33 per cent stake in its India arm.
- FIPB to decide on GlaxoSmithKline, other pharma FDI proposalsFIPB will take up tomorrow GlaxoSmithKline's Rs 6,400 crore FDI plan, the largest foreign investment proposal in the pharma sector this fis...
- GlaxoSmithKline seeks FIPB nod to hike stake in Indian armGlaxoSmithKline has approached the FIPB to hike stake in its domestic arm by buying 24.33 per cent for an estimated Rs 6,400 crore.
- GSK's open offer for buying stake in Indian arm from February 7-21GlaxoSmithKline Plc's Rs 6,389.02 crore open offer to pick up 24.33 per cent stake in its Indian arm GlaxoSmithKline Pharma will start from...
- GlaxoSmithKline Biologicals in talks to buy BE's vaccine divisionThis division produces and markets a range of paediatric and adult vaccines and has a sizeable market share in the Indian vaccine market.
- 'Glaxo to pay Rs 71.21 cr for not selling drugs at govt price'The High court in August 1981 stayed the drug prices fixed under DPCO and asked the government and Glaxo to go for a settlement.
- GlaxoSmithKline FY10 net profit up 10.37 pc to Rs 560.57 crGlaxoSmithKline Pharmaceuticals today said its consolidated net profit rose by 10.37 per cent to Rs 560.57 crore for the year ended Decembe...
- Buy Glaxo Smithkline Pharma for target of Rs 2160: APTARTBuy the stock in the range of Rs 2070-2050 with stoploss of Rs 2035 for target of Rs 2160. Price and volume breakout seen in the stock, say...
- Bullish on all pharma stocks: Jitendra MehtaTop picks at the beginning of the week was Ranbaxy followed by Aurobindo Pharma but since both of them have run up pretty well.
Load More
